

Express Mailing Label No. EL831680251US
Date of Deposit: July 11, 2001

Attorney Docket No: 21486-032 DIV4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Wands *et al.*

SERIAL NUMBER: To Be Assigned

EXAMINER: Not Yet Assigned

FILING DATE: July 11, 2001

ART UNIT: Not Yet Assigned

FOR: DIAGNOSIS AND TREATMENT OF MALIGNANT NEOPLASMS

July 11, 2001

Boston, Massachusetts

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Prior to examination, please amend the application as follows.

In the specification:

On page 1, line 2, after the title, insert:

20010711

APPLICANTS: Wands et al.

FILED: Herewith

This application is a divisional of patent application U.S. Serial Number 09/436,184, filed on November 8, 1999, the entire contents of which is hereby incorporated by reference.

APPLICANTS: Wands et al.

FILED: Herewith

In the claims:

Cancel claims 1-25 and 28-38.

Add new claims 39-45.

090919 07104

APPLICANTS: Wands et al.

FILED: Herewith

39. The method of claim 27, wherein said sequence comprises SEQ ID NO:4.
40. The method of claim 26, wherein said tumor is selected from the group consisting of colon cancer, breast cancer, pancreatic cancer, liver cancer, and cancer of the bile ducts.
41. The method of claim 26, wherein said tumor is a cancer of the central nervous system.
42. The method of claim 26, wherein said tumor is a hepatocellular carcinoma.
43. The method of claim 26, wherein said tumor is a cholangiocarcinoma.
44. The method of claim 26, wherein said tumor is a glioblastoma.
45. The method of claim 26, wherein said tumor is a neuroblastoma.

APPLICANTS: Wands et al.

FILED: Herewith

REMARKS

Claims 26-27, and 39-45 are pending, claims 1-25 and 28-38 having been canceled as being drawn to a non-elected invention. New claims 39-45 have been added. New claims 39 is supported by disclosure on page 7, line 49, to page 8, line 1, of the specification. New claims 40-41 page 1, lines 25-31, of the specification. New claims 42-43 are supported by disclosure on page 22, lines 5-6, of the specification. New claims 44-45 are supported by disclosure on page 17, line 29, and on page 42, lines 30-33, of the specification.

No new matter has been added by this amendment.

CONCLUSION

Applicants believe that the claims are in condition for allowance. The Commissioner is authorized to credit any overpayment or charge any deficiencies to Deposit Account No. 50-0311, Reference No. 21486-032.

Respectfully submitted,



Ingrid A. Beattie, Reg. No. 42,306

Attorney for Applicants

c/o MINTZ LEVIN

One Financial Center

Boston, Massachusetts 02111

Tel.: (617) 542 6000

Fax: (617) 542-2241

TRADOCS:1540151

APPLICANTS: Wands et al.

FILED: Herewith

Appendix

In the specification:

On page 1, line 2, after the title, insert:

--This application is a divisional of patent application U.S. Serial Number 09/436,184, filed on November 8, 1999, the entire contents of which is hereby incorporated by reference.--

In the claims:

Cancel claims 1-25 and 28-38.

Add new claims 39-45.

APPLICANTS: Wands et al.

FILED: Herewith

--39. The method of claim 27, wherein said sequence comprises SEQ ID NO:4.--

--40. The method of claim 26, wherein said tumor is selected from the group consisting of colon cancer, breast cancer, pancreatic cancer, liver cancer, and cancer of the bile ducts.--

--41. The method of claim 26, wherein said tumor is a cancer of the central nervous system.--

--42. The method of claim 26, wherein said tumor is a hepatocellular carcinoma.--

--43. The method of claim 26, wherein said tumor is a cholangiocarcinoma.--

--44. The method of claim 26, wherein said tumor is a glioblastoma.--

--45. The method of claim 26, wherein said tumor is a cholangiocarcinoma.--

TRA 1540151v1